This photo provided by Celltrion Inc. shows its new autoimmune disease treatment, Zymfentra. (Image courtesy of Yonhap)
SEOUL, Nov. 30 (Korea Bizwire) — Celltrion Healthcare Co. said Thursday its new autoimmune disease treatment, Zymfentra, will make its U.S. market debut on Feb. 29 next year.
Zymfentra, a subcutaneous injection formulation of Celltrion’s infliximab Remsima, won approval from the U.S. Food and Drug Administration last month.
The sales affiliate of South Korean pharmaceutical giant Celltrion Inc. said it is currently holding talks with pharmacy benefit managers in the United States to secure a spot for Zymfentra on their preferred drug list.
The company said it will work to expand Zymfentra’s subscription base stateside as the drug plays a pivotal role in Celltrion Group’s long-term strategy to reach an annual sales target of 12 trillion won (US$9.3 billion) by 2030.
(Yonhap)
